GATC Health Welcomes Genomics Expert Eric J. Mathur to its Board of Advisors

Biotechnologist, genomics expert and successful entrepreneur Eric J. Mathur has accepted a position on GATC Health’s Board of Advisors. As a GATC Advisor, Mr. Mathur will work with the company’s science, technology and management teams to review and optimize product development, introduce scientific, medical, manufacturing and marketing resources to the company and help identify strategic relationships. Mr. Mathur is currently the Chief Science Officer at Diomics Corporation.“I’ve known Eric for some time and am extremely pleased to welcome him to our advisory board,” stated John Stroh, the company’s CEO. “It is a testament to the value of our technology and vision of our leadership that we can attract scientists such as Eric, who are at the very pinnacle of their fields. Eric understands the magnitude of what we are trying to achieve and will be instrumental in helping us reach our goals.”Mr. Mathur’s career spans 40 years in basic and applied biotechnology with a focus on translational science. His expertise encompasses molecular biology, genome sciences, environmental microbiology, molecular diagnostics and high throughput drug discovery. A serial entrepreneur in the early San Diego biotech industry, Mr. Mathur participated in the formation of several start-ups including Stratagene Cloning Systems (acquired by Agilent); Diversa Corporation (acquired by BASF & British Petroleum,) and Synthetic Genomics (spinout Agradis acquired by Monsanto), among others. He is an internationally recognized speaker and accomplished biotechnologist with 50+ peer reviewed publications and over 100 issued patents.“My passion lies in leveraging genomics, biologics and polymer technologies to develop science-driven nutraceuticals, plant-based-medicines and modern therapeutics,” Noted Mr. Mathur. “This aligns perfectly with GATC Health’s mission to discover new and beneficial ways to improve health and wellness through DNA analysis. I am very pleased to join this very capable team and believe its products and services are perfectly positioned for the next generation of medicine.”

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.